


Fresenius | Factsheet Q2 / 24

COMPANY PROFILE

Fresenius is a global healthcare company. Fresenius offers solutions to the social challenges posed by a growing and aging population and the resulting need for affordable, high-quality healthcare. Fresenius comprises the Operating Companies Fresenius Kabi and Fresenius Helios as well as the Investment Company Fresenius Medical Care.

GROUP STRUCTURE



- **Fresenius Kabi** specializes in products for the therapy and care of critically and chronically ill patients. The portfolio includes biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs (generic IV drugs), and IV fluids.
- **Fresenius Helios** is Europe's leading private health care provider. The company comprises Helios Germany and Helios Spain. Helios Germany operates 85 hospitals, around 230 outpatient centers, 27 occupational health centers and 6 prevention centers. Helios Spain operates 50 hospitals, around 100 outpatient centers and around 300 occupational risk prevention centers. In addition, the company is active in Latin America with 7 hospitals and as a provider of medical diagnostics.

FRESENIUS GROUP IN FIGURES

€ in millions	Q2/24	Q2/23	Growth	FY/23
Revenue and Earnings				
Revenue ¹	5,414	5,113	8% ⁹	20,307
EBIT ¹	660	571	15% ⁸	2,266
Net income ^{1,2}	457	393	15% ⁸	1,543
Earnings per share in € ^{1,2}	0.81	0.69	15% ⁸	2.74
Balance sheet and cash flow				
Total assets	43,513 ¹⁰			45,284 ¹¹
Non-current assets	31,570 ¹⁰			32,764 ¹¹
Equity ³	19,603 ¹⁰			19,651 ¹¹
Equity ratio ³	45.1% ¹⁰			43.4% ¹¹
Net debt / EBITDA ^{1,4}	3.43x ¹⁰			3.76x ¹¹
Investments ⁵	378 ¹²	469 ¹³	-19%	1,346
Operating cash flow from continuing operations	709	148	--	2,077
Operating cash flow in % of revenue	13.1%	2.9%		10.2%
Profitability				
EBIT margin ¹	12.2%	11.2%		11.2%
Return on equity after taxes (ROE) ^{1,2,6}	8.5% ¹²			7.9%
Return on invested capital (ROIC) ^{1,6}	6.0% ¹²			5.2%
Employees ⁷	175,771 ¹⁰			193,865 ¹¹


- Before special items
- Net income attributable to shareholders of Fresenius SE & Co. KGaA
- Including noncontrolling interests
- LTM average exchange rates for both net debt and EBITDA; pro forma acquisitions / divestitures; including lease liabilities, including Fresenius Medical Care dividend⁸
- Investments in property, plant and equipment, and acquisitions
- 2023: annual return FY / 23
- All Vamed employees were taken into account until Q1/2024. From Q2 / 2024, only the employees of HES (High-End Service) and other Vamed employees who remain in Corporate are taken into account.
- Growth rate at constant currency adjusted for the divestment of the fertility services group Eugin, the hospital stake in Peru, hyperinflation in Argentina and the announced Vamed exit
- Organic growth; adjusted for the divestment of the fertility services group Eugin, the hospital stake in Peru, hyperinflation in Argentina and the announced Vamed exit
- June 30, 2024
- December 31, 2023
- H1/2024
- H1/2023

OPERATING COMPANIES


€ in millions	Q2/24	Q2/23	Growth	FY/23
FRESENIUS KABI Revenue	2,101	2,001	11% ²	8,009
EBIT ¹	334	285	17% ³	1,145
FRESENIUS HELIOS Revenue	3,230	3,020	6% ⁴	11,952
EBIT ¹	357	301	18% ⁴	1,190

- Before special items
- Organic growth; adjusted for accounting effects related to Argentina hyperinflation
- Growth rates adjusted for Argentina hyperinflation
- Growth rates adjusted for the divestment of the fertility services group Eugin and the hospital stake in Peru

REVENUE BY BUSINESS SEGMENT




REVENUE BY REGION



RELATIVE SHARE PRICE PERFORMANCE VS. INDICES

31.12.2023 = 100%



■ Fresenius share ■ DAX ■ Dow Jones Industrial Average ■ STOXX Europe 600 Health Care

FRESENIUS SHARE / ADR

	Share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of shares (June 30, 2024)	563,237,277
Market capitalization (June 30, 2024)	€15.7 billion

GROUP OUTLOOK 2024


	Targets 2024	Base 2023
Revenue, growth ¹ (organic)	4 – 7%	€20,307 million
EBIT growth ¹ (cc)	6 – 10%	€2,266 million

¹ Before special items

For the outlook of the business segments please see the Half-year Financial Report H1/2024.

ANALYST RECOMMENDATIONS


Equal-weight/ Hold/
Neutral 18%



Buy/Outperform/
Overweight 82%

As of June 24, 2024

FINANCING MIX OF THE FRESENIUS GROUP



June 30, 2024: ~€13.5 billion

CONTACT



Fresenius SE & Co. KGaA
Else-Kröner-Straße 1, 61352 Bad Homburg v.d.H.
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com

Markus Georgi
Senior Vice President
Investor Relations
Telephone: +49 (0) 61 72 / 6 08-24 85
Telefax: +49 (0) 61 72 / 6 08-24 88

Follow us on Social Media:

[linkedin.com/company/fresenius-investor-relations](https://www.linkedin.com/company/fresenius-investor-relations)

twitter.com/Fresenius_IR

For more information please see the [imprint](#) on our corporate website.

FINANCIAL CALENDAR

	Dates
Report on 1st – 3rd quarter 2024	November 6, 2024

Please note that these dates could be subject to modifications.
www.fresenius.com/events-and-roadshows